Pivotal and Palobiofarma announced a new strategic collaboration to expand access of patients to novel therapies in asthma.
Adenosine is considered an important signalling molecule in human asthma, with a function in both the acute bronchoconstrictor and airway inflammatory responses. PBF-680 is an oral adenosine A1 receptor antagonist that has successfully completed single dose escalation and treatment-period phase-I trials in healthy volunteers, plus a crossover, proof-of-concept Phase-IIa trial in mild and moderate asthma patients, in whom a single dose significantly attenuated airway hyperresponsiveness to AMP challenge and increased 8-hour post-challenge on Forced Expiratory Volume in 1 second (FEV1).
“The combined expertise in drug development and clinical research excellence of Palobiofarma and Pivotal will enable us to accelerate research and provide access to novel investigational agents,” said Dr José Javier García, MD, VP Data Management and Biostatistics at Pivotal, “We look forward to impacting positively the lives of people facing asthma throughout Europe”.
Founded in 2001 and headquartered in Madrin (Spain), Pivotal is a leading full-services CRO offering services to the healthcare industry across Europe.
Based in Barcelona, Palobiofarma is a Spanish biotechnology company founded in 2006 by a group of scientists with experience in drug discovery in several pharmaceutical companies.